P/B
5
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
$2.1B
Market Cap • 9/11/2026
2011
(15 years)
Founded
2009
(17 years ago)
IPO
NASDAQ
Listing Exchange
Canada
Country
Valuation
P/S
7,5
P/EBITDA
14
P/OCF
14,3
P/FCF
14,3
P/E
7
BVPS
3,2
EPS
2,3
Market Cap
Market Cap
2,1B
EV
1,9B
EV/Revenue
6,5
EV/EBITDA
12,2
EV/EBIT
13,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
1,6%
Total Yield
1,6%
Payout
0%
Retained Earnings
-406,5M
Profitability
Gross Margin
90,2%
EBITDA Margin
53,5%
EBIT Margin
47,8%
Net Margin
105,6%
D&A/EBITDA
0%
R&D/Revenue
12,5%
Capex/Revenue
0,1%
Capex/D&A
1%
Capex/OCF
0,1%
SBC/OCF
9,4%
% PPE
8,7%
% Goodwill
0%
ROE
78,9%
ROIC
150,2%
Growth
CAGR Revenue 5Y
37,9%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
5,4
Quick Ratio
4,8
Interest Coverage
3582,1%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!